Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ORIC-101

Small molecule · Antagonist of glucocorticoid receptor (NR3C1) · developed by ORIC Pharmaceuticals

Phase 1 Most advanced trial (none active)

ORIC Developer

1 Registered trials

What is ORIC-101?

ORIC-101 is a mifepristone-based glucocorticoid receptor antagonist that selectively binds to and inhibits GR-mediated proliferative and anti-apoptotic gene expression. It is studied in prostate cancer and other tumors where GR overexpression may drive proliferation and treatment resistance.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: glucocorticoid receptor (NR3C1), androgen receptor (AR) (secondary target)
Mechanism: Antagonist of glucocorticoid receptor (NR3C1)
Pathways: GR-mediated gene expression, proliferation inhibition, apoptosis
Therapy area: Oncology
Developer: ORIC Pharmaceuticals (ORIC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: VI6E2D3CYP

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04033328	Phase 1	Prostatic Neoplasms	Terminated	ORIC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostatic Neoplasms

Other drugs acting on NR3C1

Beclomethasone Dipropionate FDA approved Budesonide FDA approved IDP-118 FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone FDA approved Mometasone Furoate FDA approved Relacorilant FDA approved Chronocort Phase 3 Exicorilant Phase 1/2 Miricorilant Phase 2

More from ORIC Pharmaceuticals

Enozertinib Phase 1/2 ORIC-533 Phase 1 Rinzimetostat Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ORIC page.

Follow ORIC, the company behind ORIC-101

See ORIC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ORIC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z